The FDA on May 21, 2021 granted accelerated approval to RYBREVANT® for adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer, with EGFR exon 20 insertion mutations, that progressed on or after platinum-based chemotherapy. RYBREVANT® is a product of Janssen Biotech, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
